Who should not take PEG-MGF?
Documented caution flags for PEG-MGF include active malignancy and diabetic retinopathy. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for PEG-MGF is limited.
Documented caution flags for PEG-MGF
- Active malignancy
- Diabetic retinopathy
- Pregnancy / nursing
Reported side effects to weigh
- Hypoglycemia at higher doses
- Localized growth at injection site
- Headache
- Theoretical: cardiac and other tissue growth at chronic high dose
References
- Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation — Yang SY & Goldspink G, FEBS Letters, 2002
- Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? — Zabłocka B, Goldspink PH, Goldspink G, Górecki DC, Frontiers in Endocrinology, 2012
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PEG-MGF
Last updated 2026-06-15.